Highlights Astellas Pharma Inc.

Equities

4503

JP3942400007

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
1,506 ^JPY	+3.51%		+1.72%	-10.68%

Apr. 25	Astellas Pharma Inc. Announces Board and Committee Retirements	CI
Apr. 25	European Commission Approves Astellas Pharma Label Extension for Xtandi	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Commission Approves Astellas Pharma Label Extension for Xtandi	Apr. 24	MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	Apr. 23	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	Apr. 22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22	CI
Lupin Launches Mirabegron Extended-Release Tablets in US	Apr. 21	MT
Japan Inc makes a renewed U.S. push as China fears mount	Apr. 17	RE
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	Apr. 15	MT
Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Apr. 12	CI
U.S. FDA Accepts Astellas? Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy	Mar. 31	CI
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China	Mar. 28	MT
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer	Mar. 28	CI
Final dividend	Mar. 27	FA
Astellas Pharma Inc.'s Vyloy?? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer	Mar. 26	CI
Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI? in Additional Recurrent Early Prostate Cancer Treatment Setting	Mar. 22	CI
Bayer to seek approval for menopausal relief drug after third trial win	Mar. 19	RE
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas	Mar. 18	CI
Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan	Mar. 03	CI
Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application for PADCEV with KEYTRUDA	Feb. 15	CI
Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer	Jan. 30	CI
Astellas Pharma Inc. Announces Strategic Collaboration with Mass General Brigham	Jan. 30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Astellas Pharma Inc.

Equities

4503

JP3942400007

Highlights

Filters